# Catheter-Related Bloodstream Infection with Leclercia adecarboxylata and Enterobacter cloacae Complex Co-Infection: A Case Report and Literature Review

**Authors:** Po-Hsiu Huang, Po-Yu Liu, Hsien-Po Huang

PMC · DOI: 10.3390/microorganisms14020402 · Microorganisms · 2026-02-08

## TL;DR

A rare case of bloodstream infection caused by two bacteria in a cancer patient is reported, emphasizing the importance of considering uncommon pathogens in catheter-related infections.

## Contribution

First documented case of co-infection by Leclercia adecarboxylata and Enterobacter cloacae complex in a catheter-related bloodstream infection.

## Key findings

- Both isolates were susceptible to β-lactams, quinolones, and aminoglycosides.
- The patient recovered after ciprofloxacin treatment and chemoport removal.
- The case highlights the clinical relevance of rare environmental Gram-negative organisms in immunocompromised hosts.

## Abstract

Catheter-related bloodstream infections (CRBSIs) caused by Leclercia adecarboxylata are uncommon, and polymicrobial cases are even rarer. We report the first documented case caused by co-infection with Leclercia adecarboxylata and Enterobacter cloacae complex (ECC) in a woman with breast cancer undergoing chemotherapy through an indwelling chemoport. Antimicrobial susceptibility testing revealed that both isolates were susceptible to β-lactams, quinolones, and aminoglycosides. The patient achieved complete clinical recovery following intravenous ciprofloxacin therapy and prompt removal of the chemoport. This case highlights the emerging clinical relevance of Leclercia adecarboxylata and Enterobacter cloacae complex as potential pathogens capable of causing polymicrobial bloodstream infections in immunocompromised hosts and underscores the importance of considering rare environmental Gram-negative organisms as potential causes of catheter-related infections, particularly in patients with malignancy or long-term vascular access.

## Linked entities

- **Chemicals:** ciprofloxacin (PubChem CID 2764), quinolones (PubChem CID 6038)
- **Diseases:** breast cancer (MONDO:0004989)
- **Species:** Leclercia adecarboxylata (taxon 83655), Enterobacter cloacae complex (taxon 354276)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, GEN1 (GEN1 structure-specific endonuclease) [NCBI Gene 348654] {aka Gen}, CPZ (carboxypeptidase Z) [NCBI Gene 8532]
- **Diseases:** injury to (MESH:D014947), ECC (MESH:C537748), malignancy (MESH:D009369), cyanosis (MESH:D003490), head, eyes, ears, nose, or throat (MESH:D006258), swelling (MESH:D004487), lymphadenopathy (MESH:D008206), jaundice (MESH:D007565), clubbing (MESH:D003025), pneumonia (MESH:D011014), fever (MESH:D005334), Co-Infection (MESH:D060085), abnormalities of (MESH:D000014), CRBSI (MESH:D055499), ECC infections (MESH:D007239), end-stage renal disease (MESH:D007676), L. adecarboxylata bacteremia (MESH:D016470), chills (MESH:D023341), urinary tract infections (MESH:D014552), breast cancer (MESH:D001943), tenderness (MESH:D063806), erythema (MESH:D004890), Bloodstream Infection (MESH:D018805)
- **Chemicals:** cefoxitin (MESH:D002440), aminoglycosides (MESH:D000617), piperacillin (MESH:D010878), FEP (MESH:D011138), ceftolozane-tazobactam (MESH:C000594038), norfloxacin (MESH:D009643), PEF (MESH:D015366), amoxicillin-clavulanate (MESH:D019980), ciprofloxacin (MESH:D002939), lincosamides (MESH:D055231), ertapenem (MESH:D000077727), nalidixic acid (MESH:D009268), CAZ (MESH:D002442), levofloxacin (MESH:D064704), cefepime (MESH:D000077723), meropenem (MESH:D000077731), tobramycin (MESH:D014031), CCL (MESH:D002433), gentamicin (MESH:D005839), moxifloxacin (MESH:D000077266), AMK (-), cefotaxime (MESH:D002439), ceftazidime-avibactam (MESH:C000595613), aztreonam (MESH:D001398), ATM (MESH:C020809), NA (MESH:D012964), fosfomycin (MESH:D005578), trimethoprim (MESH:D014295), piperacillin-tazobactam (MESH:D000077725), ceftriaxone (MESH:D002443), macrolides (MESH:D018942), TMP (MESH:D013938), amikacin (MESH:D000583), quinolones (MESH:D015363), CL (MESH:D002713), CET (MESH:D002512), rifampin (MESH:D012293), ampicillin (MESH:D000667), AMP (MESH:D000249), imipenem (MESH:D015378), ampicillin-sulbactam (MESH:C035444), ofloxacin (MESH:D015242), cefixime (MESH:D020682), glycopeptides (MESH:D006020), ETP (MESH:D005000), cefazolin (MESH:D002437), trimethoprim-sulfamethoxazole (MESH:D015662), cefoperazone (MESH:D002438), beta-lactams (MESH:D047090)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Enterobacter cloacae complex (species group) [taxon 354276], Enterococcus faecalis (species) [taxon 1351], Enterobacterales (order) [taxon 91347], Pantoea agglomerans (species) [taxon 549], Staphylococcus aureus (species) [taxon 1280], Leclercia adecarboxylata (species) [taxon 83655], Enterobacter cloacae (species) [taxon 550], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606], Enterobacteriaceae (enterobacteria, family) [taxon 543], Atlantibacter hermannii (CDC Enteric Group 11, species) [taxon 565], Acinetobacter baumannii (species) [taxon 470]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943131/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943131/full.md

---
Source: https://tomesphere.com/paper/PMC12943131